Data gathered: July 26
Alternative Data for Amgen
About Amgen
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
| Price | $334.85 |
| Target Price | Sign up |
| Volume | 1,510,000 |
| Market Cap | $180B |
| Year Range | $258.94 - $335.97 |
| Dividend Yield | 2.68% |
| PE Ratio | 47.88 |
| Earnings Date | August 6 '24 |
| Industry | Biotechnology |
In the news
 |
Amgen Inc. Forecasted to Earn Q4 2024 Earnings of $4.80 Per Share (NASDAQ:AMGN)July 26 - ETF Daily News |
 |
Amgen (AMGN) Stock Moves -0.39%: What You Should KnowJuly 25 - Yahoo |
 |
Amgen Surges As Weight-Loss Trials Drive ExcitementJuly 25 - Yahoo |
|
Q3 2024 EPS Estimates for Amgen Inc. (NASDAQ:AMGN) Raised by AnalystJuly 24 - ETF Daily News |
Market Whales and Their Recent Bets on AMGN OptionsJuly 24 - Benzinga |
|
September 6th Options Now Available For Amgen (AMGN)July 24 - Stock Options Channel |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 6.76B | 6.21B | 548M | -113M | 1.96B | 3.960 |
| Q4 '23 | 7.63B | 6.5B | 1.13B | 767M | 2.77B | 4.710 |
| Q3 '23 | 6.33B | 3.88B | 2.44B | 1.73B | 3.4B | 4.960 |
| Q2 '23 | 6.35B | 3.84B | 2.51B | 1.38B | 3.06B | 5.000 |
| Q1 '23 | 5.68B | 3.67B | 2B | 2.84B | 4.68B | 3.980 |
Insider Transactions View All
| Grygiel Nancy A. filed to sell 9,883 shares at $313.1. May 3 '24 |
| Grygiel Nancy A. filed to sell 10,874 shares at $273. December 4 '23 |
| Graham Jonathan P filed to sell 28,078 shares at $272.8. November 13 '23 |
| Gordon Murdo filed to sell 44,308 shares at $262.4. August 11 '23 |
| Khosla Rachna filed to sell 6,630 shares at $292.9. November 10 '22 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Jun 5, 24 | Sell | $15K - $50K |
| Rohit Khanna Democrat |
May 6, 24 | $15K - $50K | |
| Thomas Tuberville Republican |
Feb 14, 24 | Sell | $15K - $50K |
Read more about Amgen (AMGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Amgen?
The Market Cap of Amgen is $180B.
What is Amgen's PE Ratio?
As of today, Amgen's PE (Price to Earnings) ratio is 47.88.
When does Amgen report earnings?
Amgen will report its next earnings on August 6 '24.
What is the current stock price of Amgen?
Currently, the price of one share of Amgen stock is $334.85.
How can I analyze the AMGN stock price chart for investment decisions?
The AMGN stock price chart above provides a comprehensive visual representation of Amgen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amgen shares. Our platform offers an up-to-date AMGN stock price chart, along with technical data analysis and alternative data insights.
Does AMGN offer dividends to its shareholders?
Yes, Amgen (AMGN) offers dividends to its shareholders, with a dividend yield of 2.68%. This dividend yield represents Amgen's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Amgen in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Amgen?
Some of the similar stocks of Amgen are Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.